X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (388) 388
humans (347) 347
life sciences & biomedicine (344) 344
male (242) 242
female (239) 239
middle aged (213) 213
aged (182) 182
cardiovascular system & cardiology (174) 174
cardiac & cardiovascular systems (152) 152
risk factors (146) 146
abridged index medicus (142) 142
adult (104) 104
cardiovascular disease (91) 91
general & internal medicine (71) 71
prospective studies (70) 70
medicine, general & internal (67) 67
mortality (65) 65
treatment outcome (64) 64
research (63) 63
cardiovascular diseases (57) 57
epidemiology (57) 57
peripheral vascular disease (53) 53
blood pressure (52) 52
cardiovascular (51) 51
hypertension (51) 51
health aspects (50) 50
angiotensin-converting enzyme inhibitors - therapeutic use (48) 48
follow-up studies (46) 46
analysis (45) 45
care and treatment (44) 44
heart attacks (43) 43
prognosis (41) 41
studies (41) 41
cardiology (40) 40
medical research (39) 39
randomized controlled trials as topic (36) 36
time factors (36) 36
diabetes (35) 35
drug therapy (35) 35
cardiovascular diseases - epidemiology (34) 34
cardiac patients (33) 33
canada (32) 32
clinical trials (32) 32
drug therapy, combination (30) 30
internal medicine (30) 30
myocardial infarction (30) 30
risk assessment (30) 30
stroke (30) 30
physical sciences (29) 29
cholesterol (28) 28
heart failure (28) 28
prevention (28) 28
risk (28) 28
diet (27) 27
benzimidazoles - therapeutic use (26) 26
double-blind method (26) 26
health risk assessment (26) 26
surveys and questionnaires (26) 26
benzoates - therapeutic use (25) 25
cross-sectional studies (25) 25
ramipril - therapeutic use (25) 25
canada - epidemiology (24) 24
coronary heart disease (24) 24
multivariate analysis (24) 24
cardiovascular diseases - mortality (23) 23
cardiovascular diseases - prevention & control (23) 23
hypertension - drug therapy (23) 23
public, environmental & occupational health (23) 23
atherosclerosis (22) 22
disease progression (22) 22
clinical medicine (21) 21
cohort studies (21) 21
exercise (21) 21
heart diseases (21) 21
technology (21) 21
usage (21) 21
cardiovascular diseases - drug therapy (20) 20
coronary artery disease (20) 20
developing countries (20) 20
heart (20) 20
klinisk medicin (20) 20
obesity (20) 20
patient outcomes (20) 20
aged, 80 and over (19) 19
cardiovascular agents - therapeutic use (19) 19
coronary angiography (19) 19
patients (19) 19
proportional hazards models (19) 19
retrospective studies (19) 19
angioplasty, balloon, coronary (18) 18
blood pressure - drug effects (18) 18
cardiology and cardiovascular medicine (18) 18
global health (18) 18
heart failure - drug therapy (18) 18
logistic models (18) 18
socioeconomic factors (18) 18
transluminal angioplasty (18) 18
adolescent (17) 17
antihypertensive agents - therapeutic use (17) 17
congestive heart failure (17) 17
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet (British edition), ISSN 0140-6736, 2011, Volume 378, Issue 9798, pp. 1231 - 1243
Summary Background Although most cardiovascular disease occurs in low-income and middle-income countries, little is known about the use of effective secondary... 
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Data Collection | Secondary Prevention | Stroke - drug therapy | Urban Population | Antihypertensive Agents - therapeutic use | Drug Utilization | Cardiovascular Agents - therapeutic use | Developed Countries | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Rural Population | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Coronary Disease - drug therapy | Adult | Female | Aged | Developing Countries | Platelet Aggregation Inhibitors - therapeutic use | Adrenergic beta-Antagonists - therapeutic use | Care and treatment | Research | Cardiovascular diseases | Health aspects | Cardiovascular agents | Studies | Low income groups | Stroke | Households | Socioeconomic factors | Data collection | Cardiovascular disease | Epidemiology | Economic development | Community | Drug use | Index Medicus | Abridged Index Medicus | Antihypertensive Agents/therapeutic use | Angiotensin-Converting Enzyme Inhibitors/therapeutic use | Cardiovascular Agents/therapeutic use | Coronary Disease/drug therapy | Cardiovascular Diseases/prevention & control | Platelet Aggregation Inhibitors/therapeutic use | Stroke/drug therapy | MEDICIN OCH HÄLSOVETENSKAP | Adrenergic beta-Antagonists/therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use | MEDICAL AND HEALTH SCIENCES
Journal Article
The Lancet (British edition), ISSN 0140-6736, 07/2015, Volume 386, Issue 9990, pp. 266 - 273
Journal Article
by Miller, Victoria and Mente, Andrew and Dehghan, Mahshid and Rangarajan, Sumathy and Zhang, Xiaohe and Swaminathan, Sumathi and Dagenais, Gilles and Gupta, Rajeev and Mohan, Viswanathan and Lear, Scott and Bangdiwala, Shrikant I and Schutte, Aletta E and Wentzel-Viljoen, Edelweiss and Avezum, Alvaro and Altuntas, Yuksel and Yusoff, Khalid and Ismail, Noorhassim and Peer, Nasheeta and Chifamba, Jephat and Diaz, Rafael and Rahman, Omar and Mohammadifard, Noushin and Lana, Fernando and Zatonska, Katarzyna and Wielgosz, Andreas and Yusufali, Afzalhussein and Iqbal, Romaina and Lopez-Jaramillo, Patricio and Khatib, Rasha and Rosengren, Annika and Kutty, V Raman and Li, Wei and Liu, Jiankang and Liu, Xiaoyun and Yin, Lu and Teo, Koon and Anand, Sonia and Yusuf, Salim and Diaz, R and Orlandini, A and Linetsky, B and Toscanelli, S and Casaccia, G and Cuneo, JM Maini and Rahman, O and Yusuf, R and Azad, AK and Rabbani, KA and Cherry, HM and Mannan, A and Hassan, I and Talukdar, AT and Tooheen, RB and Khan, MU and Sintaha, M and Choudhury, T and Haque, R and Parvin, S and Avezum, A and Oliveira, GB and Marcilio, CS and Mattos, AC and Teo, K and Yusuf, S and Dejesus, J and Agapay, D and Tongana, T and Solano, R and Kay, I and Trottier, S and Rimac, J and Elsheikh, W and Heldman, L and Ramezani, E and Dagenais, G and Poirier, P and Turbide, G and Auger, D and De Bluts, A LeBlanc and Proulx, MC and Cayer, M and Bonneville, N and Lear, S and Gasevic, D and Corber, E and de Jong, V and Vukmirovich, I and Wielgosz, A and Fodor, G and Pipe, A and Shane, A and Lanas, F and Seron, P and Martinez, S and Valdebenito, A and Oliveros, M and Wei, Li and Lisheng, Liu and Chunming, Chen and Xingyu, Wang and ... and Prospective Urban Rural Epidemiology (PURE) study investigators and PURE Study Investigators and Sahlgrenska akademin and Institute of Medicine, Department of Molecular and Clinical Medicine and Institutionen för medicin, avdelningen för molekylär och klinisk medicin and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy
The Lancet (British edition), ISSN 0140-6736, 11/2017, Volume 390, Issue 10107, pp. 2037 - 2049
Journal Article
The Lancet (British edition), ISSN 0140-6736, 01/2016, Volume 387, Issue 10013, pp. 61 - 69
Summary Background WHO has targeted that medicines to prevent recurrent cardiovascular disease be available in 80% of communities and used by 50% of eligible... 
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Drug Costs | Platelet Aggregation Inhibitors - economics | Cardiovascular Diseases - drug therapy | Humans | Income | Malaysia | Secondary Prevention | Aspirin - supply & distribution | Urban Population | Angiotensin-Converting Enzyme Inhibitors - supply & distribution | Angiotensin-Converting Enzyme Inhibitors - economics | Sweden | Pakistan | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Iran | Rural Population | China | Adrenergic beta-Antagonists - economics | Brazil | Poland | Aspirin - therapeutic use | Aspirin - economics | Chile | Platelet Aggregation Inhibitors - therapeutic use | Adrenergic beta-Antagonists - therapeutic use | Cardiovascular Agents - economics | Colombia | Argentina | Platelet Aggregation Inhibitors - supply & distribution | Hydroxymethylglutaryl-CoA Reductase Inhibitors - supply & distribution | Hydroxymethylglutaryl-CoA Reductase Inhibitors - economics | United Arab Emirates | Adrenergic beta-Antagonists - supply & distribution | India | Pharmacies | Canada | Cardiovascular Agents - supply & distribution | Cardiovascular Agents - therapeutic use | Bangladesh | Family Characteristics | Developed Countries | Turkey | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | South Africa | Zimbabwe | Developing Countries | Drugs | Prevention | Usage | Cardiovascular diseases | Analysis | Disease prevention | Cardiovascular disease | Costs | Health care access | Preventive medicine | Health risk assessment | Index Medicus | Abridged Index Medicus | Klinisk medicin | Clinical Medicine
Journal Article
The Lancet global health, ISSN 2214-109X, 10/2016, Volume 4, Issue 10, pp. e695 - e703
Journal Article